204 related articles for article (PubMed ID: 18256696)
1. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.
Coulter JA; McCarthy HO; Worthington J; Robson T; Scott S; Hirst DG
Gene Ther; 2008 Apr; 15(7):495-503. PubMed ID: 18256696
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer.
Worthington J; Robson T; Scott S; Hirst D
Gene Ther; 2005 Oct; 12(19):1417-23. PubMed ID: 15902277
[TBL] [Abstract][Full Text] [Related]
3. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.
Worthington J; Robson T; O'Keeffe M; Hirst DG
Gene Ther; 2002 Feb; 9(4):263-9. PubMed ID: 11896465
[TBL] [Abstract][Full Text] [Related]
4. p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.
McCarthy HO; Worthington J; Barrett E; Cosimo E; Boyd M; Mairs RJ; Ward C; McKeown SR; Hirst DG; Robson T
Gene Ther; 2007 Feb; 14(3):246-55. PubMed ID: 17006546
[TBL] [Abstract][Full Text] [Related]
5. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
McCarthy HO; Coulter JA; Worthington J; Robson T; Hirst DG
J Gene Med; 2007 Jun; 9(6):511-20. PubMed ID: 17471586
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
Greco O; Joiner MC; Doleh A; Powell AD; Hillman GG; Scott SD
Gene Ther; 2006 Feb; 13(3):206-15. PubMed ID: 16307003
[TBL] [Abstract][Full Text] [Related]
7. [Anti-tumor effect of suicide gene therapy using chimeric promoter plus radiotherapy on cancer cell lines].
Sun WJ; Xiong J; Wang WF; Liao ZK; Zhou FX; Zhou YF
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):245-50. PubMed ID: 21575492
[TBL] [Abstract][Full Text] [Related]
8. [Oncostatin M gene therapy in mice bearing lung adenocarcinoma xenograft using a hypoxia/radiation dual-sensitive promoter].
Wang WD; Chen ZT; Li DZ; Duan YZ; Wang ZX; Cao ZH
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Apr; 27(4):240-3. PubMed ID: 15144614
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
10. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy.
Scott SD; Joiner MC; Marples B
Gene Ther; 2002 Oct; 9(20):1396-402. PubMed ID: 12365005
[TBL] [Abstract][Full Text] [Related]
11. Development of synthetic promoters for radiation-mediated gene therapy.
Marples B; Scott SD; Hendry JH; Embleton MJ; Lashford LS; Margison GP
Gene Ther; 2000 Mar; 7(6):511-7. PubMed ID: 10757025
[TBL] [Abstract][Full Text] [Related]
12. Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer.
Xiong J; Sun WJ; Wang WF; Liao ZK; Zhou FX; Kong HY; Xu Y; Xie CH; Zhou YF
Cancer; 2012 Jan; 118(2):536-48. PubMed ID: 21717442
[TBL] [Abstract][Full Text] [Related]
13. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment.
Worthington J; McCarthy HO; Barrett E; Adams C; Robson T; Hirst DG
J Gene Med; 2004 Jun; 6(6):673-80. PubMed ID: 15170738
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin.
Greco O; Powell TM; Marples B; Joiner MC; Scott SD
Cancer Gene Ther; 2005 Jul; 12(7):655-62. PubMed ID: 15818381
[TBL] [Abstract][Full Text] [Related]
15. Combining radiation therapy with interstitial radiation-inducible TNF-α expression for locoregional cancer treatment.
Jung M; Dimtchev A; Velena A; Dritschilo A
Cancer Gene Ther; 2011 Mar; 18(3):189-95. PubMed ID: 21052099
[TBL] [Abstract][Full Text] [Related]
16. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
Yakkundi A; McErlane V; Murray M; McCarthy HO; Ward C; Hughes CM; Patterson LH; Hirst DG; McKeown SR; Robson T
Cancer Gene Ther; 2006 Jun; 13(6):598-605. PubMed ID: 16410820
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.
Adams C; McCarthy HO; Coulter JA; Worthington J; Murphy C; Robson T; Hirst DG
J Gene Med; 2009 Feb; 11(2):160-8. PubMed ID: 19062185
[TBL] [Abstract][Full Text] [Related]
18. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
Cullis ER; Kalber TL; Ashton SE; Cartwright JE; Griffiths JR; Ryan AJ; Robinson SP
Microvasc Res; 2006 Mar; 71(2):76-84. PubMed ID: 16530791
[TBL] [Abstract][Full Text] [Related]
19. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake.
Egami T; Ohuchida K; Mizumoto K; Onimaru M; Toma H; Nishio S; Nagai E; Matsumoto K; Nakamura T; Tanaka M
Clin Cancer Res; 2008 Mar; 14(6):1859-67. PubMed ID: 18347189
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
